Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 14/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16469283 | 1.00 | LMNA (0.42) | LMNASMN1; SMN2SIGMAR1POLBCRBN | |
| SCHEMBL925648 | 0.86 | F10 (0.44) | LMNASIGMAR1 | |
| SCHEMBL633653 | 0.86 | F10 (0.44) | LMNASIGMAR1 | |
| SCHEMBL591825 | 0.85 | LMNA (0.41) | LMNAPOLB | |
| SCHEMBL591826 | 0.85 | LMNA (0.41) | LMNAPOLB | |
| SCHEMBL633311 | 0.85 | F10 (0.42) | LMNASIGMAR1POLB | |
| SCHEMBL633310 | 0.85 | F10 (0.42) | LMNASIGMAR1POLB | |
| SCHEMBL16469444 | 0.81 | SIGMAR1 (0.41) | SIGMAR1 | |
| SCHEMBL16469443 | 0.81 | SIGMAR1 (0.41) | SIGMAR1 | |
| SCHEMBL2169305 | 0.81 | F10 (0.44) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776431-B1 | 2-OXO-OXAZOLIDIN-3,5-DIYL ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2016-05-04 | — | — | EP | disclosed |
| US-9079922-B2 | 2-oxo-oxazolidin-3,5-diyl antibiotic derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2015-07-14 | — | — | US | disclosed |
| US-20150051188-A1 | 2-OXO-OXAZOLIDIN-3,5-DIYL ANTIBIOTIC DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051188-A1 | 2-OXO-OXAZOLIDIN-3,5-DIYL ANTIBIOTIC DERIVATIVES | OXA1L, PYM1, MRPL21 | LMNA 1198/4885SMN1; SMN2 3529/4885SIGMAR1 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.